In the only trial I know of for BAT in CS men, this followup report is encouraging for the long-term results of those who have used BAT.
Batman BAT study updated: In the only... - Advanced Prostate...
Batman BAT study updated
Over median follow-up of 95 months, the median PFS on ADT for the entire cohort was 47.8. Median OS has not been reached (NR). Median OS for Non-Responders is 43 months versus NR (not reached) for responders (hazard ratio [HR]: 0.176, p = 0.002). Post-BAT, the PSA50 and PSA90 responses to abiraterone or enzalutamide were 94.4% and 66.7%, respectively and median PFS was 20.6 months. Patients with peak PSA level of ≥9 ng/ml after BAT had median PFS of 20.6 months versus NR for those having PSA < 9 ng/ml (HR: 0.122, p < 0.001). Median OS was 79.6 months for patients with PSA peak of ≥9 ng/ml versus NR for those having PSA peak of <9 ng/ml (HR: 0.409, p = 0.131).
Would someone please clarify these results
Clarify the terminology or clarify the implications?
Implications in plain English.
My interpretation is that those who responded to BAT then lived longer than those who did not, and those who responded to BAT then responded better to abi or enza. Those whose PSA after BAT exceeded or equaled 9 ng/ml progressed sooner and survived less time than those whose PSA after BAT was less than 9. Somewhat seems only logical, but shows that, for some, BAT continues to help after completion.
If lucky enough to get a positive result to treatments, you live longer..... I started BAT on Saturday. Wish me luck..
I read this BAT trial summary 3 times and still not sure I understand it. I’m really interested in the implications of this (as I am sure most people on this forum are because ADT is SOC for most of us).Appreciate the post! I did find this Patients Guide to BAT from the Uof MN. onlinelibrary.wiley.com/doi...
Thanks Rolphs, very helpful.